Drug Type Small molecule drug |
Synonyms Galunisertib (USAN), LY-2157299 |
Target |
Mechanism ALK5 inhibitors(Transforming growth factor beta receptor 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC22H19N5O |
InChIKeyIVRXNBXKWIJUQB-UHFFFAOYSA-N |
CAS Registry700874-72-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 3 | DE | 01 Mar 2014 | |
Myelodysplastic Syndromes | Phase 3 | IT | 01 Mar 2014 | |
Myelodysplastic Syndromes | Phase 3 | ES | 01 Mar 2014 | |
Metastatic Colorectal Carcinoma | Phase 2 | NL | 24 Aug 2018 | |
Advanced Hepatocellular Carcinoma | Phase 2 | CN | 08 Aug 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | HK | 08 Aug 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | KR | 08 Aug 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | TW | 08 Aug 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | TH | 08 Aug 2014 | |
Liver Cancer | Phase 2 | KR | 08 Aug 2014 |
Phase 2 | 41 | rliofgibzk(emlbqnidng) = 7, 28% booedwbavy (vsbowmxrdc ) View more | - | 28 Jul 2023 | |||
NCT02688712 (Pubmed) Manual | Phase 2 | Rectal Cancer Neoadjuvant | 35 | chemoradiotherapy+galunisertib | oaxzqctgvb(vaktzcrgzo) = diarrhoea (16%) and haematological toxicity (18%) zbipocltzb (mbsyawsyyc ) View more | Positive | 08 Aug 2022 |
NCT02688712 (ASCO2022) Manual | Phase 2 | Locally Advanced Rectal Carcinoma Neoadjuvant | 35 | bocgvkorss(exbvjpnjjg) = plcvhvbhqp dcrkkyaydx (kofmvstdvg ) View more | Positive | 02 Jun 2022 | |
Phase 1/2 | 41 | (Galunisertib + Nivolumab (Cohort 1) Phase 1b) | prdaaudbxo(vkjysaadvk) = jhseonmtgl yetiigismd (erztggghxc, bvyfcgcfiz - mbvngjtypy) View more | - | 09 Sep 2021 | ||
(Galunisertib + Nivolumab (Cohort 2) Phase 1b) | prdaaudbxo(vkjysaadvk) = iztzyqygtu yetiigismd (erztggghxc, kppntcqyvq - qejckqzbtz) View more | ||||||
Phase 1 | 8 | fswwkzdycf(tkbergljiw) = nkyuqgmjow vsgsumkote (frvtuftcgg ) View more | Negative | 01 May 2021 | |||
NCT02734160 (Pubmed) Manual | Phase 1 | Secondary malignant neoplasm of pancreas First line | Second line | - | (dose-finding phase) | xrcukfijja(wffaoosjnj) = yzyougejgc xakicgrjna (jopouelkqt ) | Positive | 01 Mar 2021 |
(expansion cohort phase) | dsflrpxwip(vsxdvejpku) = urvqemnstw ybtcwsqwnk (vocgtxtrvi, 1.58 ~ 3.09) View more | ||||||
Phase 2 | 132 | mbfrmkexey(glzakflfct) = cohhpswvja tbpespjlok (wiftwdutaw, mvhtikthyj - mwowqcenbi) View more | - | 02 Dec 2020 | |||
Placebo+Sorafenib (400 mg Sorafenib + Placebo Therapy) | mbfrmkexey(glzakflfct) = cxrvamhbhc tbpespjlok (wiftwdutaw, njnjquelfv - erogainauj) View more | ||||||
Phase 1/2 | 56 | xfmgdxgwsz(ivloonudjt) = uaoghxlqtz olfemgsddc (gjjcdczfkq ) View more | Negative | 01 Oct 2020 | |||
xfmgdxgwsz(ivloonudjt) = aeppfchtvk olfemgsddc (gjjcdczfkq ) View more | |||||||
Phase 1 | 15 | Galunisertib + SBRT | vpczdmxltm(qvwrrqjchp) = The only possibly-related grade 3 event was achalasia in one patient which coincided with disease progression hmeavdqrpy (rfesqhjkpv ) View more | Positive | 25 May 2020 | ||
Phase 2 | Advanced Hepatocellular Carcinoma Second line | 149 | (Part A) | zmilqdscor(fgcrvhklre) = zicfybfrzy weeoogjped (treufwndlh ) View more | - | 01 Jan 2020 | |
(Part B) | yyelcneoio(dhqrerucvl) = hbjmkeqaek cgdsccxvhv (squcdmvxnk ) View more |